| Symbol
| FGFR4
| contributors: mct - updated : 21-03-2020
|
| HGNC name
| fibroblast growth factor receptor 4
|
| HGNC id
| 3691
|
| corresponding disease(s)
|
DUP5QD
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
|
| --over
|
| |
in pancreatic cancer (mediated by an intronic enhancer activated by HNF1alpha) | | tumoral
|
|
| --over
|
| |
in lung carcinoma | | tumoral
|
|
| --over
|
|
in all epithelial carcinomas  | | tumoral
|
|
|
| gain of function
| |
in several solid tumors including hepatocellular carcinoma (HCC), breast cancer, oropharyngeal squamous cell carcinoma (OPSCC), and pancreatic cancer ( | |
| Susceptibility
|
to cancer invasion to hepatocellular carcinoma coupled with liver cirrhosis |
| Variant & Polymorphism
other
| Gly388Arg polymorphism most likely contributes to susceptibility to cancer |
|
-R388 risk variant is a unique inducer of MMP14 and collagen invasion |
|
polymorphism in FGFR4 rs351855 may be associated with the risk of HCC coupled with liver cirrhosis |
| 
|
| Candidate gene
| for limb malformation in terminal del5q patients |
| Marker
| is a potential prognostic marker for colorectal cancer |
Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| digestive | liver | | |
| inhibition of FGFR4 activation may be an effective way to prevent or treat nonalcoholic fatty liver disease (NAFLD) | | cancer | digestive | liver | |
| frequent overexpression in patients renders its inhibition a novel and much needed pharmacological approach against hepatocellular carcinoma | | cancer | reproductive | breast | |
| targeting FGFR4 in breast cancer cells overexpressing FGF19 may represent an effective strategy to suppress cancer development, progression, and metastasis | | cancer | digestive | colon | |
| therapeutic marker for colorectal cancer |
| |
|
| Fgfr4-deficient mice exhibit an elevated bile acid synthesis due to the upregulation of CYP7A1 in the liver, indicating that activation of hepatocyte FGFR4 negatively regulates bile acid synthesis |